ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1644

Mycophenolic Acid and Ribavirin Induces Cytoplasmic Autoimmunogenic Rods and Rings Structures in Vivo

Gerson D Keppeke Sr.1, Eunice Nunes2, Maria Lucia Ferraz3, Sandro F. Perazzio1, Mônica Prado1, Edward K.L. Chan4 and Luis Eduardo C. Andrade5, 1Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 2Gastroenterology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, 3Gastroenterology Division, Universidade Federal de São Paulo, São Paulo, Brazil, 4Oral Biology, University of Florida, Gainesville, FL, 5Fleury Laboratories, Sao Paulo, Brazil

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANA, autoantibodies, autoantigens and systemic lupus erythematosus (SLE), Hepatitis C

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

Autoantibodies to IMPDH2 occur in Hepatitis C patients receiving ribavirin (RBV) & interferon-α (IFN-α). Anti-IMPDH2 antibodies recognize “rods and rings” (RR) cytoplasmic structures in indirect immunofluorescence on HEp-2 cells (IIF-HEp-2). In vitro inhibition of IMPDH2 by RBV or mycophenolic acid (MPA) induces RR formation. We investigate the in vivo formation of RR structures in patients and mice treated with RBV or MPA.

Methods

Sequentially retrieved RBV/IFN-α-treated HCV (n=108) and MPA-treated Systemic Lupus Erythematosus (SLE) patients (n=78) were tested for anti-RR autoantibodies. Peripheral blood mononuclear cells (PBMC) from 18 MPA-treated SLE and 17 RBV/IFN-α-treated HCV patients were analyzed for RR+ PBMC by double-labeling IIF with human anti-RR serum and rabbit anti-IMPDH2 IgG. Cryosections from 3 untreated and 3 RBV-treated (0.4 mg/day; 3 months) BALB/c mice were screened for RR. 

Results

Forty-one (38%) HCV and none of the SLE patients presented anti-RR autoantibody (p<0.0001). In vivo RR formation in PBMC occurred in all RBV/IFN-α-treated HCV (28.2±15.2% RR+ cells) and MPA-treated SLE (22.3±15.1% RR+ cells) patients (p=0.13). The frequency of RR+ PBMC in HCV correlated with the duration of treatment (r=0.55; p=0.01). In SLE there was no correlation with duration of treatment (r=-0.01; p=0.95), time interval from last dose ingested prior to sample collection (r=0.04; p=0.86) and daily dose (r=0.30; p=0.21). RBV-treated mice showed widespread RR structures, with variable proportion of RR+ cells in the several tissues: spleen (21.5%), stomach (57.8%), liver (70.7%), kidney (38.8%), heart (13.3%), brain (56.2%), muscle (23.7%), skin (37.1%). Untreated mice showed RR only in spleen (16.3%) and pancreas (14.9%).

Conclusion

Ribavirin and MPA generate in vivo formation of IMPDH2-rich RR structures in PBMC from HCV and SLE patients, respectively. In addition, RBV-treated mice show widespread formation of RR with variable proportion of RR-positive cell across the several tissues. These findings support further studies for the investigation of the consequences of widespread RR formation in patients receiving chronic treatment with RBV or MPA, as well as the understanding of the role of in vivo RR structures on the generation of anti-IMPDH2 autoantibodies.


Disclosure:

G. D. Keppeke Sr.,
None;

E. Nunes,
None;

M. L. Ferraz,
None;

S. F. Perazzio,
None;

M. Prado,
None;

E. K. L. Chan,
None;

L. E. C. Andrade,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mycophenolic-acid-and-ribavirin-induces-cytoplasmic-autoimmunogenic-rods-and-rings-structures-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology